Oncolytics Biotech announces press release available

• Oncolytics Biotech disclosed FDA Fast Track designation for pelareorep with a checkpoint inhibitor in second-line or later anal cancer.
• Designation targets inoperable locally recurrent or metastatic squamous cell anal canal cancer following progression or intolerance to prior systemic therapy.
• Company cited GOBLET data showing about 30% objective response rate, median duration of response about 15.5 months, 12-month overall survival 82%.
• Program targets an estimated US commercial opportunity approaching USD 1 billion annually, with no FDA-approved therapies post first-line standard of care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.